Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Cash from Investing Activities (2020 - 2024)

HCW Biologics (HCWB) has disclosed Cash from Investing Activities for 5 consecutive years, with -$113412.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Cash from Investing Activities rose 96.95% year-over-year to -$113412.0, compared with a TTM value of -$113412.0 through Sep 2025, up 97.06%, and an annual FY2024 reading of -$261617.0, down 106.89% over the prior year.
  • Cash from Investing Activities was -$113412.0 for Q4 2024 at HCW Biologics, down from -$37063.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $9.4 million in Q3 2023 and bottomed at -$35.0 million in Q3 2021.
  • Average Cash from Investing Activities over 5 years is -$995079.2, with a median of -$37063.0 recorded in 2024.
  • The sharpest move saw Cash from Investing Activities crashed 33138.35% in 2021, then surged 34363.87% in 2022.
  • Year by year, Cash from Investing Activities stood at -$36391.0 in 2020, then skyrocketed by 34.31% to -$23904.0 in 2021, then crashed by 187.35% to -$68687.0 in 2022, then crashed by 5309.54% to -$3.7 million in 2023, then soared by 96.95% to -$113412.0 in 2024.
  • Business Quant data shows Cash from Investing Activities for HCWB at -$113412.0 in Q4 2024, -$37063.0 in Q3 2024, and $18567.0 in Q2 2024.